Lomitapide for the treatment of homozygous familial hypercholesterolaemia in children
- PMID: 39426394
- DOI: 10.1016/S2213-8587(24)00277-8
Lomitapide for the treatment of homozygous familial hypercholesterolaemia in children
Conflict of interest statement
LRB has served on advisory boards Amgen, HLS Therapeutics, Novartis, and UltraGenyx, and has received honoraria for continuing medical education talks from Amgen, HLS Therapeutics, Novartis, and UltraGenyx. RAH has served on advisory boards for Acasti, Akcea-Ionis, Amgen, Arrowhead, HLS Therapeutics, Medison, Novartis, Pfizer, Sanofi, Regeneron, and UltraGenyx, and has received honoraria for continuing medical education talks from Amgen, HLS Therapeutics, Novartis, and Pfizer.
Comment on
-
Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study.Lancet Diabetes Endocrinol. 2024 Dec;12(12):880-889. doi: 10.1016/S2213-8587(24)00233-X. Epub 2024 Oct 16. Lancet Diabetes Endocrinol. 2024. PMID: 39426393 Clinical Trial.